

## PRESS RELEASE

**Collectis SA Shareholders General Meeting  
of February 16, 2015**

**February 17, 2015 – Paris (France)** – Collectis SA Shareholders' General Meeting (Alternext: ALCLS.PA) had been held on Monday, February 16, 2015 in Paris, at its head office.

At the end of the meeting, during which more than 65% of voting rights were exercised, 20 of the 21 resolutions had been adopted.

20 resolutions received more than 96,9% votes in favor. Resolution No. 21, regarding a capital increase reserved for members of a company savings plan, was rejected.

In particular, Collectis' shareholders voted on:

- Authorization of a share repurchase plan and authorization given to the Board of Directors to retire the shares acquired through it;
- Delegations of authority given to the Board of Directors to increase share capital, in particular in the context of an IPO in the United States.
- Resolutions enable Collectis to grant its executive officers and employees attractive incentive plans.

The [full results of the vote](http://www.collectis.com) can be examined on the company's website ([www.collectis.com](http://www.collectis.com)).

**For further information, please contact:****Collectis**

Jennifer Moore

Phone: +33 (0)1 81 69 16 00

e-mail: [media@collectis.com](mailto:media@collectis.com)

**BMC Communications - New York City**

Brad Miles

Phone: 646-513-3125

e-mail: [bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)

**About Collectis**

Collectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered Tcells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the NYSE Alternext market (ticker: ALCLS).

**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains



forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.